Shinagawa K, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Fukutani H, Tabata M, Hirano A, Mizunuma N
Japanese Foundation for Cancer Research, Division of Clinical Chemotherapy, Tokyo.
Gan To Kagaku Ryoho. 1988 Dec;15(12):3277-81.
Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy). The therapy was repeated every 3 weeks until progression or until a cumulative dose of 700 mg/m2 for epirubicin. Of 25 evaluable patients, there were one with complete response (CR), 11 with partial response (PR), 10 with no change and 3 with progressive disease (PD). The overall response rate (CR + PR) was 48%, and the median duration of response was 47 weeks. The median survival time was 78 weeks for responders and 60 weeks for non-responders, and the difference was statistically significant (p = 0.02). Leukopenia, alopecia, nausea and vomiting were commonly observed, but these side effects were better tolerated than those accompanying ACF therapy. As for cardiotoxicity, there were no acute abnormal E.C.G. changes and no congestive heart failure occurred. The median cumulative dose of Epirubicin was 510 mg/m2. These results indicate that ECF therapy is as effective as ACF therapy for metastatic breast cancer with considerably better tolerability.
29例转移性乳腺癌患者接受了联合化疗，具体方案为：第1天静脉注射表柔比星50mg/m²，第1天静脉注射环磷酰胺500mg/m²，每天口服喃氟啶800mg（ECF疗法）。每3周重复一次治疗，直至病情进展或表柔比星累积剂量达到700mg/m²。在25例可评估患者中，1例完全缓解（CR），11例部分缓解（PR），10例病情无变化，3例病情进展（PD）。总缓解率（CR+PR）为48%，中位缓解持续时间为47周。缓解者的中位生存时间为78周，未缓解者为60周，差异具有统计学意义（p=0.02）。常见白细胞减少、脱发、恶心和呕吐，但这些副作用的耐受性优于ACF疗法。关于心脏毒性，未观察到急性心电图异常变化，也未发生充血性心力衰竭。表柔比星的中位累积剂量为510mg/m²。这些结果表明，ECF疗法对转移性乳腺癌的疗效与ACF疗法相当，且耐受性明显更好。
